Cargando…
Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists
CONTEXT: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in a global health emergency, the like of which has never been seen before. Prostate cancer (PCa) services across the globe have been on hold due to changing medical and surgical priorities. There is also...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296308/ https://www.ncbi.nlm.nih.gov/pubmed/34173542 http://dx.doi.org/10.1016/j.euros.2020.05.005 |
_version_ | 1783546823121567744 |
---|---|
author | Dovey, Zachary Mohamed, Nihal Gharib, Yasmine Ratnani, Parita Hammouda, Nada Nair, Sujit S. Chakravarty, Dimple Sobotka, Stanislaw Lantz, Anna Wiklund, Peter Kyprianou, Natasha Tewari, Ash |
author_facet | Dovey, Zachary Mohamed, Nihal Gharib, Yasmine Ratnani, Parita Hammouda, Nada Nair, Sujit S. Chakravarty, Dimple Sobotka, Stanislaw Lantz, Anna Wiklund, Peter Kyprianou, Natasha Tewari, Ash |
author_sort | Dovey, Zachary |
collection | PubMed |
description | CONTEXT: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in a global health emergency, the like of which has never been seen before. Prostate cancer (PCa) services across the globe have been on hold due to changing medical and surgical priorities. There is also epidemiological evidence that PCa patients have increased incidence and mortality from SARS-CoV-2 infection due to gender differences, age, and higher propensity for risk factors (eg, respiratory disease, obesity, hypertension, and smoking status). OBJECTIVE: To contribute to the emerging body of knowledge on the risks of SARS-CoV-2 infection to PCa patients and, in the face of PCa treatment delays, provide evidence-based recommendations for ongoing management of specific PCa patient groups. EVIDENCE ACQUISITION: A literature search was performed using all sources (MEDLINE, EMBASE, ScienceDirect, Cochrane Libraries, and Web of Science) as well as the media to harness emerging data on the SARS-CoV-2 pandemic and its influence on PCa. Eligibility criteria were originality of data and relevance to PCa management. The authors note that during these unprecedented times, retrospective data are constantly being updated from multiple sources globally. EVIDENCE SYNTHESIS: A total of 72 articles and data sources were found initially. Owing to repetition, lack of originality, or nonrelevance, six articles were rejected, leaving 23 retrospective studies, seven basic science research articles, 15 societal and journal guidelines, and 21 epidemiological data sources, from countries at different stages of SARS-CoV-2 pandemic. These were analyzed qualitatively to produce evidence-based guidelines for the management of PCa patients at different stages of the patient journey, with strategies to reduce the risk of viral spread. CONCLUSIONS: PCa patients may have an increased risk of SARS-CoV-2 infection as well as morbidity and mortality if infected. Once appropriately triaged, and to reduce viral spread, PCa patients can have surveillance by telemedicine, and institute lifestyle changes and social quarantining measures. If risk stratification suggests that treatment should be planned, androgen deprivation therapy can be started, or potentially surgery or radiation therapy is possible on a case-by-case basis. PATIENT SUMMARY: Prostate cancer patients can be followed up remotely until the severe acute respiratory syndrome coronavirus 2 pandemic resolves, but higher-risk cases may have treatment expedited to limit any negative impact on prostate cancer outcomes. |
format | Online Article Text |
id | pubmed-7296308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-72963082020-06-16 Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists Dovey, Zachary Mohamed, Nihal Gharib, Yasmine Ratnani, Parita Hammouda, Nada Nair, Sujit S. Chakravarty, Dimple Sobotka, Stanislaw Lantz, Anna Wiklund, Peter Kyprianou, Natasha Tewari, Ash Eur Urol Open Sci Review - Prostate Cancer CONTEXT: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in a global health emergency, the like of which has never been seen before. Prostate cancer (PCa) services across the globe have been on hold due to changing medical and surgical priorities. There is also epidemiological evidence that PCa patients have increased incidence and mortality from SARS-CoV-2 infection due to gender differences, age, and higher propensity for risk factors (eg, respiratory disease, obesity, hypertension, and smoking status). OBJECTIVE: To contribute to the emerging body of knowledge on the risks of SARS-CoV-2 infection to PCa patients and, in the face of PCa treatment delays, provide evidence-based recommendations for ongoing management of specific PCa patient groups. EVIDENCE ACQUISITION: A literature search was performed using all sources (MEDLINE, EMBASE, ScienceDirect, Cochrane Libraries, and Web of Science) as well as the media to harness emerging data on the SARS-CoV-2 pandemic and its influence on PCa. Eligibility criteria were originality of data and relevance to PCa management. The authors note that during these unprecedented times, retrospective data are constantly being updated from multiple sources globally. EVIDENCE SYNTHESIS: A total of 72 articles and data sources were found initially. Owing to repetition, lack of originality, or nonrelevance, six articles were rejected, leaving 23 retrospective studies, seven basic science research articles, 15 societal and journal guidelines, and 21 epidemiological data sources, from countries at different stages of SARS-CoV-2 pandemic. These were analyzed qualitatively to produce evidence-based guidelines for the management of PCa patients at different stages of the patient journey, with strategies to reduce the risk of viral spread. CONCLUSIONS: PCa patients may have an increased risk of SARS-CoV-2 infection as well as morbidity and mortality if infected. Once appropriately triaged, and to reduce viral spread, PCa patients can have surveillance by telemedicine, and institute lifestyle changes and social quarantining measures. If risk stratification suggests that treatment should be planned, androgen deprivation therapy can be started, or potentially surgery or radiation therapy is possible on a case-by-case basis. PATIENT SUMMARY: Prostate cancer patients can be followed up remotely until the severe acute respiratory syndrome coronavirus 2 pandemic resolves, but higher-risk cases may have treatment expedited to limit any negative impact on prostate cancer outcomes. Elsevier 2020-06-16 /pmc/articles/PMC7296308/ /pubmed/34173542 http://dx.doi.org/10.1016/j.euros.2020.05.005 Text en © 2020 Published by Elsevier B.V. on behalf of European Association of Urology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review - Prostate Cancer Dovey, Zachary Mohamed, Nihal Gharib, Yasmine Ratnani, Parita Hammouda, Nada Nair, Sujit S. Chakravarty, Dimple Sobotka, Stanislaw Lantz, Anna Wiklund, Peter Kyprianou, Natasha Tewari, Ash Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists |
title | Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists |
title_full | Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists |
title_fullStr | Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists |
title_full_unstemmed | Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists |
title_short | Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists |
title_sort | impact of covid-19 on prostate cancer management: guidelines for urologists |
topic | Review - Prostate Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296308/ https://www.ncbi.nlm.nih.gov/pubmed/34173542 http://dx.doi.org/10.1016/j.euros.2020.05.005 |
work_keys_str_mv | AT doveyzachary impactofcovid19onprostatecancermanagementguidelinesforurologists AT mohamednihal impactofcovid19onprostatecancermanagementguidelinesforurologists AT gharibyasmine impactofcovid19onprostatecancermanagementguidelinesforurologists AT ratnaniparita impactofcovid19onprostatecancermanagementguidelinesforurologists AT hammoudanada impactofcovid19onprostatecancermanagementguidelinesforurologists AT nairsujits impactofcovid19onprostatecancermanagementguidelinesforurologists AT chakravartydimple impactofcovid19onprostatecancermanagementguidelinesforurologists AT sobotkastanislaw impactofcovid19onprostatecancermanagementguidelinesforurologists AT lantzanna impactofcovid19onprostatecancermanagementguidelinesforurologists AT wiklundpeter impactofcovid19onprostatecancermanagementguidelinesforurologists AT kyprianounatasha impactofcovid19onprostatecancermanagementguidelinesforurologists AT tewariash impactofcovid19onprostatecancermanagementguidelinesforurologists |